BOBULSKY SUSAN sold $115K of ADPT
BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 5,000 shares of Adaptive Biotechnologies Corp (ADPT) at $23.00 ($0.12M total) on 2026-07-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price, and that it was executed under a pre-arranged Rule 10b5-1 plan.
Market read
Traders may treat this as routine insider activity with limited fundamental implications, but it can be used for sentiment and positioning checks.
What to watch
The article does not state whether the sale was part of a larger series, nor does it provide options activity or other insider buys that could offset the signal.
Background
The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).
Ticker impact
Adaptive Biotechnologies CCO Susan Bobulsky sold 5,000 shares at $23.00 on 2026-07-16 under a 10b5-1 plan, per Form 4.
Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.
The filing is an SEC Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.
Market effects
Minimal, as the disclosure is company-specific and not a sector-wide regulatory or clinical catalyst.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with management’s view of near-term risk or valuation, so traders may still watch for follow-on sales.
Key entities
- issuerAdaptive Biotechnologies Corp
Company whose insider transaction is disclosed on Form 4.
- insiderSusan Bobulsky
Chief Commercial Officer, MRD, who sold shares.
